TerminatedPHASE2, PHASE3NCT01225276

Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP

Studying Chronic inflammatory demyelinating polyneuropathy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Octapharma
Principal Investigator
Wolfgang Frenzel, MD
Octapharma
Intervention
NewGam 10%(drug)
Enrollment
2 enrolled
Eligibility
18 years · All sexes
Timeline
20112012

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01225276 on ClinicalTrials.gov

Other trials for Chronic inflammatory demyelinating polyneuropathy

Additional recruiting or active studies for the same condition.

See all trials for Chronic inflammatory demyelinating polyneuropathy

← Back to all trials